SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.

Cancer Science
Naoto TomitaYoshiaki Ishigatsubo

Abstract

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R-CHOP) is widely accepted as standard care for diffuse large B-cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R-IPI) was established in 2007 after the addition of rituximab to standard DLBCL treatment. To reassess the utility of R-IPI, we carried out a retrospective analysis of patients with DLBCL uniformly treated with standard R-CHOP. Progression-free survival (PFS) curves in "very good" and "good" risk groups as defined by the R-IPI showed no statistical difference. We added soluble interleukin-2 receptor (sIL-2R) level to the factors comprising the R-IPI. Five levels of sIL-2R were weighed with respect to their impact on PFS. sIL-2R of >2500 U/mL was determined as the most appropriate threshold. We developed a new prognostic SIL index, which includes three independent prognostic risk factors: clinical stage (S); sIL-2R level over 2500 U/mL (I); and elevated lactate dehydrogenase level (L). This index indicates standard risk (0 or 1 risk factors, 4-year PFS 83%, 4-year overall survival 91%) and high risk (2 or 3 risk factors, 4-year PFS 52%, 4-year overall survival 67%) outcomes. The SIL index is...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel O PerskyUNKNOWN Southwest Oncology Group
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake

❮ Previous
Next ❯

Citations

Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GuptaT E Witzig
Sep 10, 2015·Leukemia Research·Kazuho MiyashitaYoshiaki Ishigatsubo
Jul 26, 2015·Annals of Hematology·Naoto TomitaYoshiaki Ishigatsubo
Sep 7, 2017·International Journal of Laboratory Hematology·K NishimuraT Eto

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Michael Pfreundschuh
© 2021 Meta ULC. All rights reserved